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THE COST-EFFECTIVENESS OF DIAGNOSTIC
STRATEGIES WITH ANGIOGRAPHY AND/OR
DUPLEX SCANNING FOR AORTOILIAC AND
FEMOROPOPLITEAL ARTERIAL DISEASE
Cofﬁ S, Dijkgraaf M, Ubbink D, Reekers J, Legemate D
Academic Medical Center/University of Amsterdam,
Amsterdam, Netherlands
OBJECTIVES: To assess the cost-effectiveness of three
diagnostic strategies for the aortoiliac (AI) and fem-
oropopliteal (FP) arteries in patients with peripheral arte-
rial occlusive disease (PAOD): angiography (reference),
duplex scanning (DS) plus supplementary angiography 
if DS is inconclusive, and DS plus conﬁrmative angio-
graphy if DS is positive. METHODS: Incremental cost-
effectiveness analysis from a provider perspective with the
identiﬁcation of a signiﬁcant (positive) or insigniﬁcant
(negative) diameter reduction (= the number of identiﬁed
cases) as the primary effect parameter. Sensitivity (AI:
0.86–0.91; FP: 0.80–0.85) and speciﬁcity (AI: 0.97–0.99;
FP: 0.96–0.98) data of DS were derived from a meta-
analysis. The real costs of both diagnostic modalities were
calculated from the associated personnel, material and
overhead costs at our hospital for the year 2000. Costs
were expressed in euro. RESULTS: The costs of DS were
€67.20 and €63.28 for the AI and FP tract respectively.
The cost of angiography (including a one-day admission)
was €503.10. The reference strategy resulted in an unam-
biguous diagnosis in 90% of the AI as well as FP cases
compared with 89% (AI) and 85% (FP) for the supple-
mentary strategy. Assuming the disease prevalence in the
laboratory between 70–90% however, the extra costs 
per identiﬁed case for the reference strategy compared
with the supplementary strategy ranged from €59.000–
€14.000 for the AI tract and from €8.300–€5.100 for the
FP tract. CONCLUSIONS: The reference strategy is most
effective for both, the AI and FP tracts. If society does not
want to spend over €10,000 per identiﬁed case, then for
the AI tract the supplementary strategy is the most cost-
effective one. If society is willing to spend €10,000 per
identiﬁed case, then one should prefer the reference strat-
egy for the FP tract.
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PROBABILISTIC SENSITIVITY ANALYSIS FOR
EVALUATING COST-EFFECTIVENESS IN
SECONDARY PREVENTION OF ISCHEMIC
EVENTS
Lennes X1, Carita P2, Gabriel S2
1Cresge-Labores Lille University, Lille, France; 2Sanoﬁ-
Synthelabo, Bagneux, France
OBJECTIVES: In the case of a determinist cost-
effectiveness analysis (CEA), uncertainty related to the
parameters can be handled by a probabilistic sensitivity
analysis for estimating conﬁdence interval (CI) for incre-
mental cost-effectiveness ratio (ICER). The study aim was
to assess uncertainty in a CEA from a French perspective
of two strategies in secondary prevention of ischemic
events: clopidogrel versus aspirin. METHODS: From a
Markov model based on CAPRIE trial (Clopidogrel
versus Aspirin in Patients at Risk of Ischemic Events
19185 patients), a CEA was run in order to assess the
cost per life year saved with clopidogrel versus aspirin.
We supposed that each of the parameters of the model,
instead of taking a single value, was a random variable
to which a distribution could be associated: beta distrib-
ution was used in the generation of transition probabili-
ties (the parameters of distribution depend on the study
characteristics from which the parameters issue) and tri-
angular distribution of unit cost. Using a Monte-Carlo
simulation, the joint distribution of mean incremental
cost and mean incremental effectiveness were simulated
and displayed in the cost-effectiveness plan. Ninety ﬁve
percent conﬁdence intervals were estimated using per-
centile method. RESULTS: The results of the Monte-
Carlo simulation (10000 replications) were all clustered
in the quadrant corresponding to the situation where
clopidogrel is more effective and more expensive. For a
hypothetical cohort of 1000 patients treated during 2
years, the estimation of the additional cost was equal to
€1041 per patient CI = [952; 1,130], number of life years
gained to 0,068 per patient (CI = [0,046; 0,094]). The
ICER was equal to €15,907 CI = [11,655; 21,067]. CON-
CLUSION: Conﬁdence intervals estimated from the prob-
abilistic sensitivity analysis were not too wide. This
suggested that the CEA is robust and provides reliable
data for decision-makers. Within its conﬁdence interval,
the ICER remains within acceptable range, and compares
favourably with other therapeutic strategies.
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ACCEPTANCE AND RELIABILITY OF A COST-
MEASUREMENT QUESTIONNAIRE IN CARDIAC
REHABILITATION
Schweikert B1, Hahmann HW2, Leidl R1
1University of Ulm, Ulm, Germany; 2Klinik Schwabenland,
Isny-Neutrauchburg, Germany
OBJECTIVES: Comprehensive measurement of disease
related cost in an outpatient setting is a crucial task for
economic assessment. In decentralized health systems like
in Germany provider or third party payer data are not
readily accessible suggesting a patient oriented approach.
Objective of this pilot study was to develop a retrospec-
tive cost measurement instrument for cardiac rehabilita-
tion patients which would allow reliable and—compared
to prospective measurement—time and resource saving
assessment of cost in studies with a medium to long-term
time horizon. METHODS: A cost questionnaire was
developed covering medical and non-medical resource use
retrospectively over a 12-week time period after discharge
from inpatient cardiac rehabilitation. One hundred and
six patients were included in the pilot study (mean 
age 55, male 85%, myocardial infarction 51%, bypass
